Related Experiment Video

Updated: Feb 21, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

571

Ponatinib: A Review of Efficacy and Safety

Fulvio Massaro1, Matteo Molica1, Massimo Breccia1

  • 1Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.

Current Cancer Drug Targets
|October 4, 2017
PubMed

Insights

Ponatinib effectively treats chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), including cases with the T315I mutation. This review examines its efficacy, safety, and cardiovascular considerations.

Area of Science:

  • Oncology
  • Pharmacology
  • Hematology

Background:

  • Ponatinib is a third-generation kinase inhibitor targeting BCR-ABL1 mutations, including the T315I gatekeeper mutation.
  • It is indicated for resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
  • Previous safety concerns, particularly cardiovascular thrombotic events, led to temporary suspension and subsequent risk-benefit analyses.

Purpose of the Study:

  • To review clinical trial data on ponatinib's use in CML and Ph+ ALL.
  • To discuss the drug's safety and tolerability profile.
  • To explore future perspectives for ponatinib's application.

Main Methods:

  • Review of clinical trial data.
  • Analysis of safety and tolerability studies.
  • Discussion of patient characteristics and management recommendations.

Main Results:

  • Ponatinib demonstrates inhibitory activity against native BCR-ABL1 and various mutations.
  • Clinical trials support its use in specific CML and Ph+ ALL patient populations.
  • Ongoing research focuses on managing its cardiovascular risks.

Conclusions:

  • Ponatinib is a valuable therapeutic option for specific CML and Ph+ ALL patients, especially those with T315I mutation.
  • Careful patient selection and monitoring for cardiovascular events are crucial.
  • Further research will refine its role and management in clinical practice.
Keywords:
Chronic myeloid leukemiaEPIC trialPACE trialPh+ acute lymphoblastic leukemiaT315I mutationcardiovascular eventsponatinib.

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-308:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.6K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
25
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
351
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
591
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
668